> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Info Collection Revision on Drug Reporting
- URL: https://www.fdaweb.com/info-collection-revision-on-drug-reporting/
- Published: 2021-11-05T12:00:00.000Z
- Updated: 2026-09-14T17:21:37.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150524

*Federal Register* notice: FDA has submitted to OMB an information collection revision for a guidance entitled “Postmarketing Adverse Experience Reporting and Recordkeeping for Drug and Biologics Products” (OMB Control Number 0910-0230). The collection supports statutory provisions regarding the monitoring of FDA-regulated products. The guidance was revised to provide recommendations for recordkeeping applicable to any pandemic, not just influenza, including recommendations for planning, notification, and documentation for continuity of operations for firms that report postmarketing adverse events during any pandemic. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-11-05/pdf/2021-24236.pdf?ref=fdaweb.com).